Publication:
Yields of Dual Therapy Containing High-Dose Proton Pump Inhibitor in Eradication of H. Pylori Positive Dyspeptic Patients

Simple item page
dc.contributor.authorInce, ALİ TÜZÜN
dc.contributor.authorTOZLU, Mukaddes
dc.contributor.authorBAYSAL, Birol
dc.contributor.authorSenturk, HAKAN
dc.contributor.authorArici, Sema
dc.contributor.authorOzden, Ali
dc.contributor.institutionauthorİNCE, ALİ TÜZÜN
dc.contributor.institutionauthorŞENTÜRK, HAKAN
dc.contributor.institutionauthorARICI, DILEK SEMA
dc.date.accessioned2019-10-05T21:41:24Z
dc.date.available2019-10-05T21:41:24Z
dc.date.issued2014-07-01
dc.description.abstractBackground/Aims: H. pylon eradication has been recommended for dyspeptic patients in high prevalance regions. Triple therapies are still prescribed mostly because culture and antibiotic susceptibility tests aren-t widely available in the world. Dual therapy with high-dose proton pump inhibitors reported to have higher eradication rates. Our objective was to determine eradication success and cost-effectivity of dual therapy in dyspeptic patients. Methodology: Patients were treated orally with either dual (n:74,omeprazole 20mg q.i.d and amoxicillin 1g b.i.d) or triple therapy (n:116,omeprazole 20mg b.i.d and amoxicillin 1g b.i.d and clarithromycin 500mg b.i.d) for 14 days. HpSA was requested 3 months later. The results were evaluated statistically, p values <0,05 were considered significant. Results: Patients (n:190) were included the study((80 female,110 male, mean age: 35.6 11yearr). Alcohol/smoking, endoscopic findings and H. pylon rates with pathological examinations were not significantly different between groups whereas there was significant difference in HpFast tests(p<0.01). Whe examined with HpSA tests 3 months after the treatment eradication rate was 81.1% in the dual therapy group versus 63.8% in the triple therapy group (p:0.011) Dual therapy was economic than triple therapy (144USDvs.107USD,p<0.001). Conclusions: Dual therapy seems more successful cost-effective and is less risky in terms of side effects compared to standard triple therapy in patients with dyspepsia.
dc.description.sponsorshipBezmiâlem Vakıf Üniversitesi
dc.identifier10.1016/j.bmc.2011.08.028
dc.identifier.citationInce A. T. , TOZLU M., BAYSAL B., Senturk H., Arici S., Ozden A., -Yields of Dual Therapy Containing High-Dose Proton Pump Inhibitor in Eradication of H. Pylori Positive Dyspeptic Patients-, HEPATO-GASTROENTEROLOGY, cilt.61, ss.1454-1458, 2014
dc.identifier.doi10.5754/hge14372
dc.identifier.scopus84906972360
dc.identifier.urihttps://hdl.handle.net/20.500.12645/7964
dc.identifier.wosWOS:000341170800048
dc.language.isoen
dc.titleYields of Dual Therapy Containing High-Dose Proton Pump Inhibitor in Eradication of H. Pylori Positive Dyspeptic Patients
dc.typeArticle
dspace.entity.typePublication
local.article.journalnameBioorganic &amp; medicinal chemistry
local.avesis.idc5c8c316-990d-46d3-9897-85640a4a54be
local.avesis.response7840
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication6daa6ab7-ee45-4f50-9e71-e831046b6462
relation.isAuthorOfPublication278fcf63-3b92-4368-bff6-f140ebd9aeb3
relation.isAuthorOfPublication39582b2a-f3bf-47fe-9483-87678e56820e
relation.isAuthorOfPublication.latestForDiscovery278fcf63-3b92-4368-bff6-f140ebd9aeb3
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Collections
Yayınlar - Eserler